Real-world Experience within Standard NHS Use of Traztuzumab Deruxtecan as Late Line Therapy for Advanced HER-2-positive Breast Cancer

Purpose: The authorisation of traztuzumab deruxtecan (Enhertu) in March 2021 within the NHS is based on phase II study data [1], reporting a response rate (RR) of 61%, with preliminary overall survival (OS) of 24.6 months, which is remarkable in a heavily pre-treated HER2-positive population. Although impressive, this data should be backed up by further phase III data, or through robust data from real-world use of this drug.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research